Boston Scientific Stock Price, News & Analysis (NYSE:BSX)

$25.61 0.11 (0.43 %)
(As of 12/13/2017 09:43 AM ET)
Previous Close$25.50
Today's Range$25.54 - $25.73
52-Week Range$21.03 - $29.93
Volume11.20 million shs
Average Volume7.04 million shs
Market Capitalization$35.02 billion
P/E Ratio20.9
Dividend YieldN/A
Beta0.96

About Boston Scientific (NYSE:BSX)

Boston Scientific logoBoston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BSX
CUSIP10113710
Phone508-683-4000

Debt

Debt-to-Equity Ratio0.58%
Current Ratio0.72%
Quick Ratio0.50%

Price-To-Earnings

Trailing P/E Ratio20.9
Forward P/E Ratio20.49
P/E Growth1.97

Sales & Book Value

Annual Sales$8.39 billion
Price / Sales4.19
Cash Flow$1.74 per share
Price / Cash14.71
Book Value$4.94 per share
Price / Book5.18

Profitability

Trailing EPS$0.61
Net Income$347 million
Net Margins9.55%
Return on Equity23.60%
Return on Assets9.24%

Miscellaneous

Employees27,000
Outstanding Shares1,373,200,000

Boston Scientific (NYSE:BSX) Frequently Asked Questions

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific Corporation (NYSE:BSX) released its quarterly earnings data on Thursday, October, 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.31. The medical equipment provider had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The business's revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.27 earnings per share. View Boston Scientific's Earnings History.

When will Boston Scientific make its next earnings announcement?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Thursday, February, 1st 2018. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific issued an update on its fourth quarter earnings guidance on Thursday, October, 26th. The company provided earnings per share guidance of $0.32-0.35 for the period, compared to the Thomson Reuters consensus estimate of $0.34. The company issued revenue guidance of $2.345-2.375, compared to the consensus revenue estimate of $2.32 billion.

Where is Boston Scientific's stock going? Where will Boston Scientific's stock price be in 2017?

17 Wall Street analysts have issued 12 month price objectives for Boston Scientific's shares. Their predictions range from $28.00 to $35.00. On average, they expect Boston Scientific's stock price to reach $30.90 in the next twelve months. View Analyst Ratings for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:

  • 1. According to Zacks Investment Research, "Despite back-to-back hurricances, Boston Scientific managed to registered solid third-quarter show with earnings in line with the Zacks Consensus Estimate and revenues ahead of the mark. An improving foreign exchange scenario has also started to contribute to the company’s overall top line performance. In the past three months, Boston Scientific has been trading above the broader industry. The raised guidance is indicative of this bullish trend to continue through the rest of 2017. The company is leaving no stone unturned to strengthen its core business and invest more in global markets. Among the recent developments, worth mentioning is the acquisition of Apama Medical, in the field of atrial fibrillation. On the flip side, Boston Scientific's unimpressive pacemaker performance within the core CRM continues remains a drag. This apart, the recall of the company's Lotus range of heart devices is expected to hamper sales through 2017." (10/30/2017)
  • 2. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)
  • 3. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)
  • 4. Northland Securities analysts commented, "The implications for Edwards now are a longer runway without BSX truly being on the market, potential questions arising about product design / reliability of the Lotus Valve. More importantly, Edwards now has a chance to pick up incremental share in Europe. We remain strong buyers of EW." (2/23/2017)

Are investors shorting Boston Scientific?

Boston Scientific saw a increase in short interest in the month of November. As of November 15th, there was short interest totalling 15,786,054 shares, an increase of 33.3% from the October 31st total of 11,839,217 shares. Based on an average daily volume of 7,265,104 shares, the short-interest ratio is currently 2.2 days. Approximately 1.2% of the company's shares are short sold.

Who are some of Boston Scientific's key competitors?

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the folowing people:

  • Michael F. Mahoney, Chairman of the Board, President, Chief Executive Officer (Age 52)
  • Daniel J. Brennan, Chief Financial Officer, Executive Vice President (Age 51)
  • Supratim Bose, Executive Vice President; President, Asia-Pacific, Middle East and Africa (Age 64)
  • Keith D. Dawkins M.D., Global Chief Medical Officer, Executive Vice President (Age 66)
  • Joseph M. Fitzgerald, Executive Vice President; President - Rhythm Management (Age 53)
  • Edward F. Mackey, Executive Vice President - Operations (Age 54)
  • Ian T. Meredith AM, Executive Vice President, Global Chief Medical Officer (Age 60)
  • Michael P. Phalen, Executive Vice President; President - MedSurg (Age 57)
  • Desiree Ann Ralls-Morrison, Senior Vice President, General Counsel, Corporate Secretary (Age 51)
  • Wendy Carruthers, Senior Vice President - Human Resources (Age 48)

Who owns Boston Scientific stock?

Boston Scientific's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (3.81%), Janus Henderson Group PLC (2.67%), Artisan Partners Limited Partnership (2.64%), Bank of New York Mellon Corp (1.33%), Orbimed Advisors LLC (0.98%) and Evercore Trust Company N.A. (0.82%). Company insiders that own Boston Scientific stock include Charles J Dockendorff, Daniel J Brennan, David A Pierce, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.

Who sold Boston Scientific stock? Who is selling Boston Scientific stock?

Boston Scientific's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Janus Henderson Group PLC, JPMorgan Chase & Co., APG Asset Management N.V., Boston Partners, Orbimed Advisors LLC, Point72 Asset Management L.P. and Bank of New York Mellon Corp. Company insiders that have sold Boston Scientific company stock in the last year include Daniel J Brennan, David A Pierce, John Bradley Sorenson, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific.

Who bought Boston Scientific stock? Who is buying Boston Scientific stock?

Boston Scientific's stock was acquired by a variety of institutional investors in the last quarter, including Prudential Financial Inc., American Century Companies Inc., Sirios Capital Management L P, Teachers Retirement System of The State of Kentucky, Associated Banc Corp, State of Wisconsin Investment Board, Russell Investments Group Ltd. and Stifel Financial Corp. Company insiders that have bought Boston Scientific stock in the last two years include Charles J Dockendorff and Valley Gold Master Fund L Sun. View Insider Buying and Selling for Boston Scientific.

How do I buy Boston Scientific stock?

Shares of Boston Scientific can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific's stock price today?

One share of Boston Scientific stock can currently be purchased for approximately $25.61.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $35.02 billion and generates $8.39 billion in revenue each year. The medical equipment provider earns $347 million in net income (profit) each year or $0.61 on an earnings per share basis. Boston Scientific employs 27,000 workers across the globe.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]


MarketBeat Community Rating for Boston Scientific (BSX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  578 (Vote Outperform)
Underperform Votes:  534 (Vote Underperform)
Total Votes:  1,112
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Boston Scientific (NYSE:BSX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.792.812.79
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
19 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
19 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
21 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
22 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.24$29.87$28.36$26.95
Price Target Upside: 18.07% upside7.42% upside0.48% upside2.90% downside

Boston Scientific (NYSE:BSX) Consensus Price Target History

Price Target History for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/12/2017BMO Capital MarketsReiterated RatingBuy$32.00LowView Rating Details
12/8/2017Needham & Company LLCUpgradeBuy -> Strong-Buy$25.04 -> $32.00LowView Rating Details
12/4/2017SunTrust BanksSet Price TargetBuy$33.00LowView Rating Details
11/30/2017CowenSet Price TargetBuy$31.00LowView Rating Details
11/30/2017BTIG ResearchUpgradeNeutral -> Buy$31.00MediumView Rating Details
11/29/2017J P Morgan Chase & CoReiterated RatingBuyLowView Rating Details
11/29/2017OppenheimerReiterated RatingHoldHighView Rating Details
11/29/2017Canaccord GenuityLower Price TargetBuy -> Buy$36.00 -> $35.00HighView Rating Details
11/7/2017Royal Bank of CanadaReiterated RatingBuy$31.00N/AView Rating Details
9/25/2017Stifel NicolausReiterated RatingBuy$32.00LowView Rating Details
9/7/2017Jefferies GroupReiterated RatingHoldLowView Rating Details
6/28/2017BarclaysBoost Price TargetOverweight -> Overweight$30.00 -> $31.00LowView Rating Details
6/16/2017Wells Fargo & CompanyReiterated RatingOutperform$29.50 -> $31.00LowView Rating Details
5/16/2017Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$28.00LowView Rating Details
4/28/2017Evercore ISIBoost Price TargetOutperform$26.50 -> $28.50LowView Rating Details
4/12/2017GuggenheimReiterated RatingBuyLowView Rating Details
2/23/2017Northland SecuritiesReiterated RatingPositiveN/AView Rating Details
10/6/2016CitigroupBoost Price TargetBuy$28.00 -> $29.00N/AView Rating Details
9/1/2016ArgusUpgradeHold -> Buy$23.82 -> $33.00N/AView Rating Details
7/29/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
7/29/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
7/29/2016WedbushBoost Price TargetNeutral$23.00 -> $25.00N/AView Rating Details
7/28/2016BenchmarkBoost Price TargetBuy$25.00 -> $31.00N/AView Rating Details
6/21/2016Piper Jaffray CompaniesReiterated RatingOverweight$26.00N/AView Rating Details
3/27/2016Morgan StanleyReiterated RatingOverweight$22.00N/AView Rating Details
3/25/2016Bank of AmericaReiterated RatingBuy$23.00N/AView Rating Details
3/18/2016Longbow ResearchInitiated CoverageBuyN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$22.00N/AView Rating Details
3/12/2016Deutsche BankReiterated RatingHoldN/AView Rating Details
1/4/2016Sterne Agee CRTBoost Price TargetBuy$21.00 -> $22.50N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Boston Scientific (NYSE:BSX) Earnings History and Estimates Chart

Earnings by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE BSX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/31/2018$0.34N/AView Earnings Details
10/26/2017Q3 2017$0.31$0.31$2.21 billion$2.22 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.31$0.32$2.21 billion$2.26 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.30$0.29$2.08 billion$2.16 billionViewN/AView Earnings Details
2/2/2017Q416$0.29$0.30$2.16 billion$2.19 billionViewListenView Earnings Details
10/26/2016Q316$0.27$0.27$2.07 billion$2.11 billionViewListenView Earnings Details
7/28/2016Q216$0.27$0.27$2.05 billion$2.13 billionViewListenView Earnings Details
4/27/2016Q116$0.24$0.28$1.91 billion$1.96 billionViewListenView Earnings Details
2/4/2016Q415$0.25$0.26$2.00 billion$1.98 billionViewListenView Earnings Details
10/28/2015Q315$0.23$0.24$1.86 billion$1.89 billionViewListenView Earnings Details
7/23/2015Q215$0.21$0.22$1.83 billion$1.84 billionViewListenView Earnings Details
4/28/2015Q115$0.21$0.21$1.78 billion$1.77 billionViewListenView Earnings Details
2/4/2015Q414$0.21$0.22$1.91 billion$1.89 billionViewListenView Earnings Details
10/22/2014Q314$0.20$0.20$1.82 billion$1.85 billionViewListenView Earnings Details
7/24/2014Q214$0.20$0.21$1.87 billion$1.87 billionViewListenView Earnings Details
4/29/2014Q114$0.18$0.20$1.80 billion$1.77 billionViewListenView Earnings Details
2/4/2014Q4$0.13$0.21$1.83 billion$1.84 billionViewListenView Earnings Details
10/24/2013Q313$0.09$0.17$1.73 billion$1.74 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.10$0.18$1.78 billion$1.81 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.09$0.16$1.79 billion$1.76 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.11$0.18$1.76 billion$1.82 billionViewListenView Earnings Details
10/18/2012$0.11($0.52)ViewN/AView Earnings Details
7/26/2012$0.08$0.17ViewN/AView Earnings Details
4/19/2012$0.13$0.15ViewN/AView Earnings Details
2/2/2012$0.08$0.07ViewN/AView Earnings Details
10/20/2011$0.09$0.15ViewN/AView Earnings Details
7/28/2011$0.08$0.17ViewN/AView Earnings Details
4/20/2011$0.04$0.01ViewN/AView Earnings Details
2/1/2011$0.09$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Boston Scientific (NYSE:BSX) Earnings Estimates

2017 EPS Consensus Estimate: $1.26
2018 EPS Consensus Estimate: $1.41
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20175$0.29$0.31$0.30
Q2 20175$0.31$0.31$0.31
Q3 20176$0.30$0.32$0.31
Q4 20175$0.31$0.35$0.34
Q1 20183$0.30$0.33$0.31
Q2 20183$0.36$0.37$0.36
Q3 20184$0.33$0.36$0.35
Q4 20183$0.38$0.40$0.39
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Boston Scientific (NYSE:BSX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Boston Scientific (NYSE BSX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 90.57%
Insider Trades by Quarter for Boston Scientific (NYSE:BSX)
Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE BSX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/1/2017Timothy A PrattEVPSell10,000$26.04$260,400.00View SEC Filing  
12/1/2017Valley Gold Master Fund L SunInsiderBuy27,431$0.44$12,069.64
11/29/2017Michael P. PhalenEVPSell15,500$26.66$413,230.00View SEC Filing  
11/28/2017Valley Gold Master Fund L SunInsiderBuy408,006$0.45$183,602.70
11/1/2017Timothy A PrattEVPSell10,000$28.22$282,200.00View SEC Filing  
10/30/2017Michael P. PhalenEVPSell15,500$28.42$440,510.00View SEC Filing  
10/4/2017Supratim BoseEVPSell347,137$29.12$10,108,629.44View SEC Filing  
10/2/2017Timothy A PrattEVPSell11,061$29.24$323,423.64View SEC Filing  
9/29/2017Michael P. PhalenEVPSell15,500$28.72$445,160.00View SEC Filing  
9/1/2017Timothy A PrattEVPSell10,104$27.46$277,455.84View SEC Filing  
8/31/2017Maulik NanavatySVPSell57,031$27.28$1,555,805.68View SEC Filing  
8/30/2017Maulik NanavatySVPSell27,031$27.08$731,999.48View SEC Filing  
8/29/2017Michael P. PhalenEVPSell15,500$26.87$416,485.00View SEC Filing  
8/3/2017Wendy CarruthersSVPSell12,433$26.75$332,582.75View SEC Filing  
8/2/2017John Bradley SorensonSVPSell7,900$26.37$208,323.00View SEC Filing  
8/1/2017Timothy A PrattEVPSell10,000$26.67$266,700.00View SEC Filing  
7/31/2017John Bradley SorensonSVPSell2,100$27.15$57,015.00View SEC Filing  
7/31/2017Michael P. PhalenEVPSell15,500$27.13$420,515.00View SEC Filing  
7/11/2017Daniel J BrennanCFOSell92,158$27.48$2,532,501.84View SEC Filing  
7/3/2017Timothy A PrattEVPSell10,000$27.87$278,700.00View SEC Filing  
6/29/2017Michael P. PhalenEVPSell15,500$28.02$434,310.00View SEC Filing  
6/9/2017David A PierceSVPSell13,562$28.00$379,736.00View SEC Filing  
6/2/2017David A PierceSVPSell2,972$27.70$82,324.40View SEC Filing  
6/1/2017Timothy A PrattEVPSell10,000$27.13$271,300.00View SEC Filing  
5/30/2017Michael P. PhalenEVPSell15,500$27.25$422,375.00View SEC Filing  
5/17/2017Kevin J. BallingerEVPSell28,864$26.14$754,504.96View SEC Filing  
5/1/2017Timothy A PrattEVPSell10,000$26.37$263,700.00View SEC Filing  
4/26/2017David A PierceSVPSell10,250$26.00$266,500.00View SEC Filing  
4/26/2017Michael P. PhalenEVPSell34,773$26.00$904,098.00View SEC Filing  
4/10/2017John Bradley SorensonSVPSell2,950$24.66$72,747.00View SEC Filing  
4/3/2017Timothy A PrattEVPSell10,000$24.87$248,700.00View SEC Filing  
3/29/2017Michael P. PhalenEVPSell79,045$24.55$1,940,554.75View SEC Filing  
3/3/2017David A PierceSVPSell25,012$25.01$625,550.12View SEC Filing  
3/3/2017Timothy A PrattEVPSell23,540$25.01$588,735.40View SEC Filing  
2/27/2017David A PierceSVPSell3,417$24.84$84,878.28View SEC Filing  
2/27/2017Timothy A PrattEVPSell4,832$24.84$120,026.88View SEC Filing  
2/7/2017Keith D DawkinsEVPSell80,783$25.21$2,036,539.43View SEC Filing  
1/9/2017David A PierceSVPSell10,232$22.24$227,559.68View SEC Filing  
1/9/2017Timothy A PrattEVPSell6,195$22.24$137,776.80View SEC Filing  
12/1/2016Timothy A PrattEVPSell26,726$20.48$547,348.48View SEC Filing  
8/11/2016John Bradley SorensonSVPSell2,500$23.90$59,750.00View SEC Filing  
8/1/2016Michael F MahoneyCEOSell44,400$24.44$1,085,136.00View SEC Filing  
8/1/2016Timothy A PrattEVPSell24,000$24.46$587,040.00View SEC Filing  
7/20/2016David A PierceSVPSell2,480$24.03$59,594.40View SEC Filing  
7/20/2016Michael P. PhalenEVPSell35,000$24.03$841,050.00View SEC Filing  
6/1/2016Michael F MahoneyCEOSell100,000$22.69$2,269,000.00View SEC Filing  
6/1/2016Timothy A PrattEVPSell24,229$22.66$549,029.14View SEC Filing  
5/11/2016John Bradley SorensonSVPSell2,800$22.15$62,020.00View SEC Filing  
5/10/2016Keith D DawkinsEVPSell80,000$22.15$1,772,000.00View SEC Filing  
5/6/2016Jeffrey B MirvissSVPSell24,659$21.94$541,018.46View SEC Filing  
5/3/2016Joseph Michael FitzgeraldEVPSell79,960$21.81$1,743,927.60View SEC Filing  
5/2/2016Michael F MahoneyCEOSell100,000$22.12$2,212,000.00View SEC Filing  
5/2/2016Timothy A PrattEVPSell24,000$21.93$526,320.00View SEC Filing  
4/27/2016Kevin J BallingerSVPSell111,807$21.62$2,417,267.34View SEC Filing  
4/27/2016Timothy A PrattEVPSell39,927$21.40$854,437.80View SEC Filing  
4/4/2016Jeffrey B MirvissSVPSell18,422$19.00$350,018.00View SEC Filing  
4/1/2016Michael F MahoneyCEOSell100,000$18.90$1,890,000.00View SEC Filing  
4/1/2016Timothy A PrattEVPSell24,000$18.73$449,520.00View SEC Filing  
3/11/2016Kevin J BallingerSVPSell16,705$18.00$300,690.00View SEC Filing  
3/8/2016Karen PrangeSVPSell14,747$17.27$254,680.69View SEC Filing  
3/2/2016Michael P. PhalenEVPSell10,665$17.17$183,118.05View SEC Filing  
3/1/2016Michael F MahoneyCEOSell100,000$16.96$1,696,000.00View SEC Filing  
3/1/2016Timothy A PrattEVPSell15,068$16.97$255,703.96View SEC Filing  
2/29/2016Kevin J. BallingerSVPSell2,114$17.17$36,297.38View SEC Filing  
2/29/2016Michael P. PhalenEVPSell1,819$17.19$31,268.61View SEC Filing  
2/25/2016Daniel J BrennanCFOSell103,211$17.22$1,777,293.42View SEC Filing  
2/25/2016Kevin J. BallingerSVPSell1,903$17.48$33,264.44View SEC Filing  
2/25/2016Michael P. PhalenEVPSell34,106$17.28$589,351.68View SEC Filing  
2/17/2016Kevin J. BallingerSVPSell7,616$17.37$132,289.92View SEC Filing  
2/12/2016Charles J DockendorffDirectorBuy30,000$16.49$494,700.00View SEC Filing  
2/8/2016Karen PrangeSVPSell6,216$16.05$99,766.80View SEC Filing  
1/8/2016Timothy A PrattEVPSell7,160$17.67$126,517.20View SEC Filing  
1/7/2016Kevin J BallingerSVPSell19,059$17.73$337,916.07View SEC Filing  
1/5/2016Jeffrey B MirvissSVPSell9,953$18.00$179,154.00View SEC Filing  
12/1/2015Timothy A. PrattEVPSell24,000$18.43$442,320.00View SEC Filing  
11/16/2015Ernest MarioDirectorSell125,000$17.63$2,203,750.00View SEC Filing  
11/9/2015John Bradley SorensonSVPSell4,469$18.68$83,480.92View SEC Filing  
11/9/2015Joseph Michael FitzgeraldEVPSell26,220$18.58$487,167.60View SEC Filing  
11/5/2015Timothy A PrattEVPSell19,598$19.00$372,362.00View SEC Filing  
10/28/2015Jeffrey B MirvissSVPSell9,492$18.00$170,856.00View SEC Filing  
10/28/2015Timothy A PrattEVPSell3,500$18.00$63,000.00View SEC Filing  
10/5/2015Timothy A PrattEVPSell3,500$17.34$60,690.00View SEC Filing  
10/1/2015Timothy A. PrattEVPSell17,000$16.33$277,610.00View SEC Filing  
8/21/2015John E AbeleDirectorBuy200,000$16.77$3,354,000.00View SEC Filing  
8/19/2015John E AbeleDirectorBuy200,000$17.48$3,496,000.00View SEC Filing  
8/17/2015John E AbeleDirectorBuy100,000$17.50$1,750,000.00View SEC Filing  
7/7/2015Karen PrangeSVPSell17,456$17.66$308,272.96View SEC Filing  
5/29/2015Maulik NanavatySVPSell71,558$18.52$1,325,254.16View SEC Filing  
5/28/2015Wendy CarruthersSVPSell42,281$17.91$757,252.71View SEC Filing  
5/18/2015Ernest MarioDirectorSell50,000$18.09$904,500.00View SEC Filing  
5/14/2015John E SununuDirectorSell10,000$17.87$178,700.00View SEC Filing  
5/11/2015John Bradley SorensonSVPSell8,735$17.49$152,775.15View SEC Filing  
3/20/2015David A PierceSVPSell18,050$18.00$324,900.00View SEC Filing  
3/20/2015Michael P PhalenEVPSell46,085$17.94$826,764.90View SEC Filing  
3/16/2015Michael P PhalenEVPSell30,022$17.18$515,777.96View SEC Filing  
3/13/2015John Bradley SorensonSVPSell3,830$16.84$64,497.20View SEC Filing  
3/9/2015David A PierceSVPSell2,561$16.54$42,358.94View SEC Filing  
3/3/2015David A PierceSVPSell8,983$16.79$150,824.57View SEC Filing  
3/3/2015Michael P PhalenEVPSell12,768$16.79$214,374.72View SEC Filing  
2/27/2015David A PierceSVPSell19,046$16.80$319,972.80View SEC Filing  
2/27/2015Michael P PhalenEVPSell1,819$16.80$30,559.20View SEC Filing  
2/19/2015David A PierceSVPSell11,958$16.46$196,828.68View SEC Filing  
2/19/2015Michael P PhalenEVPSell13,188$16.44$216,810.72View SEC Filing  
2/10/2015Joseph Michael FitzgeraldEVPSell61,208$14.66$897,309.28View SEC Filing  
2/9/2015David A PierceSVPSell5,000$14.66$73,300.00View SEC Filing  
2/6/2015Kevin J BallingerSVPSell21,408$15.06$322,404.48View SEC Filing  
1/20/2015Michael P PhalenEVPSell10,000$14.54$145,400.00View SEC Filing  
1/8/2015David A PierceSVPSell18,612$14.31$266,337.72View SEC Filing  
1/8/2015Michael P PhalenEVPSell27,589$14.31$394,798.59View SEC Filing  
1/5/2015Michael P PhalenEVPSell10,000$13.75$137,500.00View SEC Filing  
12/10/2014Karen PrangeSVPSell19,753$12.64$249,677.92View SEC Filing  
12/8/2014David A PierceSVPSell5,000$12.90$64,500.00View SEC Filing  
12/1/2014Ernest MarioDirectorSell10,000$12.96$129,600.00View SEC Filing  
11/28/2014Michael F MahoneyCEOBuy11,700$12.89$150,813.00View SEC Filing  
11/10/2014Edward J LudwigDirectorBuy10,000$13.38$133,800.00View SEC Filing  
11/5/2014John E SununuDirectorSell8,997$13.38$120,379.86View SEC Filing  
11/3/2014Ernest MarioDirectorSell10,000$13.30$133,000.00View SEC Filing  
10/8/2014Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
9/2/2014Ernest MarioDirectorSell10,000$12.60$126,000.00View SEC Filing  
8/15/2014Michael P PhalenEVPSell11,471$12.58$144,305.18View SEC Filing  
8/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
7/30/2014David A PierceSVPSell157$12.97$2,036.29View SEC Filing  
7/15/2014Michael P PhalenEVPSell67,500$13.04$880,200.00View SEC Filing  
7/1/2014Ernest MarioDirectorSell10,000$12.95$129,500.00View SEC Filing  
6/16/2014Michael P PhalenEVPSell13,500$13.02$175,770.00View SEC Filing  
6/2/2014Ernest MarioDirectorSell10,000$12.88$128,800.00View SEC Filing  
5/15/2014Michael PhalenEVPSell13,500$12.76$172,260.00View SEC Filing  
5/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
4/15/2014Michael PhalenEVPSell13,500$13.25$178,875.00View SEC Filing  
4/1/2014Ernest MarioDirectorSell10,000$13.55$135,500.00View SEC Filing  
3/17/2014Michael PhalenEVPSell13,500$13.05$176,175.00View SEC Filing  
3/6/2014David PierceSVPSell5,316$13.44$71,447.04View SEC Filing  
3/6/2014Michael PhalenEVPSell7,281$13.44$97,856.64View SEC Filing  
2/27/2014David PierceSVPSell2,057$13.29$27,337.53View SEC Filing  
2/27/2014Michael PhalenEVPSell3,166$13.29$42,076.14View SEC Filing  
2/21/2014David PierceSVPSell3,199$13.22$42,290.78View SEC Filing  
2/21/2014Michael PhalenEVPSell3,222$13.22$42,594.84View SEC Filing  
2/18/2014Michael PhalenEVPSell13,500$13.30$179,550.00View SEC Filing  
2/13/2014Kristina JohnsonDirectorSell18,000$13.01$234,180.00View SEC Filing  
2/6/2014Ernest MarioDirectorSell17,104$12.80$218,931.20View SEC Filing  
2/3/2014Ernest MarioDirectorSell10,000$13.19$131,900.00View SEC Filing  
1/6/2014Ernest MarioDirectorSell10,000$12.50$125,000.00View SEC Filing  
12/26/2013Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
11/26/2013Jeffrey CapelloCFOSell85,106$11.82$1,005,952.92View SEC Filing  
11/11/2013Jeffrey MirvissSVPSell26,000$11.91$309,660.00View SEC Filing  
8/29/2013Jeffrey CapelloCFOSell525,000$10.68$5,607,000.00View SEC Filing  
8/16/2013Joseph Michael FitzgeraldSVPSell9,202$11.02$101,406.04View SEC Filing  
8/14/2013Kevin BallingerSVPSell38,171$11.28$430,568.88View SEC Filing  
5/31/2013Jeffrey B MirvissSVPSell10,941$9.37$102,517.17View SEC Filing  
5/30/2013Wendy CarruthersSVPSell25,001$9.16$229,009.16View SEC Filing  
5/29/2013Nelda J ConnorsDirectorSell24,116$9.17$221,143.72View SEC Filing  
5/6/2013Ernest MarioDirectorBuy30,000$7.76$232,800.00View SEC Filing  
11/13/2012Nj Nicholas JrDirectorBuy20,000$5.28$105,600.00View SEC Filing  
11/9/2012Nj Nicholas JrDirectorBuy25,000$5.17$129,250.00View SEC Filing  
8/6/2012Ernest MarioDirectorBuy32,000$5.29$169,280.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Boston Scientific (NYSE BSX) News Headlines

Source:
DateHeadline
Boston Scientific (BSX) Receives Buy Rating from BMO Capital MarketsBoston Scientific (BSX) Receives Buy Rating from BMO Capital Markets
www.americanbankingnews.com - December 12 at 8:38 PM
Earnings Growth Keep Boston Scientific (BSX) a BuyEarnings Growth Keep Boston Scientific (BSX) a Buy
investorplace.com - December 12 at 12:00 PM
Boston Scientific Stock Up As FDA OKs Vercise Deep Brain Stimulation SystemBoston Scientific Stock Up As FDA OKs Vercise Deep Brain Stimulation System
www.nasdaq.com - December 12 at 10:15 AM
Boston Scientific shares rise on U.S. approval for Parkinson’s disease treatmentBoston Scientific shares rise on U.S. approval for Parkinson’s disease treatment
finance.yahoo.com - December 12 at 10:15 AM
Boston Scientific Receives U.S. FDA Approval for the Vercise™ Deep Brain Stimulation SystemBoston Scientific Receives U.S. FDA Approval for the Vercise™ Deep Brain Stimulation System
finance.yahoo.com - December 11 at 5:14 PM
Financial Comparison: Boston Scientific (BSX) versus Viveve Medical (VIVE)Financial Comparison: Boston Scientific (BSX) versus Viveve Medical (VIVE)
www.americanbankingnews.com - December 9 at 6:24 PM
6 Reasons Why Needham Upgraded Boston Scientific6 Reasons Why Needham Upgraded Boston Scientific
finance.yahoo.com - December 9 at 9:50 AM
Boston Scientific (BSX) Rating Lowered to C+ at TheStreetBoston Scientific (BSX) Rating Lowered to C+ at TheStreet
www.americanbankingnews.com - December 9 at 9:22 AM
Boston Scientific (BSX) Lifted to Strong-Buy at Needham & Company LLCBoston Scientific (BSX) Lifted to Strong-Buy at Needham & Company LLC
www.americanbankingnews.com - December 8 at 11:12 PM
6 Reasons Why Needham Upgraded Boston Scientific - Benzinga6 Reasons Why Needham Upgraded Boston Scientific - Benzinga
www.benzinga.com - December 8 at 4:57 PM
$2.35 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter$2.35 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter
www.americanbankingnews.com - December 6 at 5:00 AM
Boston Scientific (BSX) Given a $33.00 Price Target at SunTrust BanksBoston Scientific (BSX) Given a $33.00 Price Target at SunTrust Banks
www.americanbankingnews.com - December 5 at 6:34 PM
Boston Scientific’s (BSX) Robust Earnings Growth Keep it a BuyBoston Scientific’s (BSX) Robust Earnings Growth Keep it a Buy
investorplace.com - December 5 at 11:39 AM
Insider Selling: Boston Scientific Corporation (BSX) EVP Sells 10,000 Shares of StockInsider Selling: Boston Scientific Corporation (BSX) EVP Sells 10,000 Shares of Stock
www.americanbankingnews.com - December 4 at 9:02 PM
Boston Scientific Corporation (BSX) Expected to Announce Earnings of $0.34 Per ShareBoston Scientific Corporation (BSX) Expected to Announce Earnings of $0.34 Per Share
www.americanbankingnews.com - December 4 at 5:10 PM
Boston Scientific Corporation to Post FY2019 Earnings of $1.49 Per Share, Jefferies Group Forecasts (BSX)Boston Scientific Corporation to Post FY2019 Earnings of $1.49 Per Share, Jefferies Group Forecasts (BSX)
www.americanbankingnews.com - December 4 at 2:54 PM
Boston Scientific Corporation (BSX) Insider Valley Gold Master Fund L. Sun Acquires 27,431 SharesBoston Scientific Corporation (BSX) Insider Valley Gold Master Fund L. Sun Acquires 27,431 Shares
www.americanbankingnews.com - December 4 at 12:04 PM
Q4 2017 EPS Estimates for Boston Scientific Corporation Lowered by Leerink Swann (BSX)Q4 2017 EPS Estimates for Boston Scientific Corporation Lowered by Leerink Swann (BSX)
www.americanbankingnews.com - December 4 at 3:12 AM
FY2018 Earnings Estimate for Boston Scientific Corporation Issued By Wedbush (BSX)FY2018 Earnings Estimate for Boston Scientific Corporation Issued By Wedbush (BSX)
www.americanbankingnews.com - December 1 at 10:16 PM
Research Analysts Set Expectations for Boston Scientific Corporations Q3 2018 Earnings (BSX)Research Analysts Set Expectations for Boston Scientific Corporation's Q3 2018 Earnings (BSX)
www.americanbankingnews.com - December 1 at 7:52 PM
Boston Scientific Corporation Forecasted to Post Q3 2018 Earnings of $0.36 Per Share (BSX)Boston Scientific Corporation Forecasted to Post Q3 2018 Earnings of $0.36 Per Share (BSX)
www.americanbankingnews.com - December 1 at 7:26 PM
Boston Scientific (BSX) Given a $31.00 Price Target by Cowen AnalystsBoston Scientific (BSX) Given a $31.00 Price Target by Cowen Analysts
www.americanbankingnews.com - December 1 at 6:24 PM
Lightning Round: Jim Cramer Weighs In On Boston Scientific, Masco, ADP And More - BenzingaLightning Round: Jim Cramer Weighs In On Boston Scientific, Masco, ADP And More - Benzinga
www.benzinga.com - December 1 at 5:08 PM
Why Boston Scientific Stock Fell 9% in Two DaysWhy Boston Scientific Stock Fell 9% in Two Days
finance.yahoo.com - December 1 at 5:08 PM
How Wall Street Reacted to the Delay in BSX’s Lotus Edge LaunchHow Wall Street Reacted to the Delay in BSX’s Lotus Edge Launch
finance.yahoo.com - December 1 at 5:08 PM
Boston Scientific Target of Unusually Large Options Trading (BSX)Boston Scientific Target of Unusually Large Options Trading (BSX)
www.americanbankingnews.com - December 1 at 5:15 AM
Stock Traders Buy High Volume of Boston Scientific Put Options (BSX)Stock Traders Buy High Volume of Boston Scientific Put Options (BSX)
www.americanbankingnews.com - December 1 at 5:15 AM
BTIG Research Upgrades Boston Scientific (BSX) to "Buy"BTIG Research Upgrades Boston Scientific (BSX) to "Buy"
www.americanbankingnews.com - November 30 at 7:34 PM
Insider Selling: Boston Scientific Corporation (BSX) EVP Sells 15,500 Shares of StockInsider Selling: Boston Scientific Corporation (BSX) EVP Sells 15,500 Shares of Stock
www.americanbankingnews.com - November 30 at 4:42 PM
Valley Gold Master Fund L. Sun Acquires 408,006 Shares of Boston Scientific Corporation (BSX) StockValley Gold Master Fund L. Sun Acquires 408,006 Shares of Boston Scientific Corporation (BSX) Stock
www.americanbankingnews.com - November 30 at 4:40 PM
BMO Capital Markets Reiterates Buy Rating for Boston Scientific (BSX)BMO Capital Markets Reiterates Buy Rating for Boston Scientific (BSX)
www.americanbankingnews.com - November 30 at 3:56 PM
Boston Scientific Corporation (BSX) Receives Average Rating of "Buy" from AnalystsBoston Scientific Corporation (BSX) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 30 at 2:48 PM
Boston Scientific: S&P 500’s Top Loser on November 28Boston Scientific: S&P 500’s Top Loser on November 28
finance.yahoo.com - November 29 at 5:22 PM
JPMorgan: Buy The Boston Scientific DipJPMorgan: Buy The Boston Scientific Dip
finance.yahoo.com - November 29 at 5:22 PM
New Products, Pricing Growth To Boost Boston Scientifics Cardiovascular SegmentNew Products, Pricing Growth To Boost Boston Scientific's Cardiovascular Segment
finance.yahoo.com - November 29 at 5:22 PM
Boston Scientifics Jaw-Dropping Stock Dive Is Buying Opportunity: JPMorganBoston Scientific's Jaw-Dropping Stock Dive Is Buying Opportunity: JPMorgan
finance.yahoo.com - November 29 at 5:22 PM
J P Morgan Chase & Co Reiterates Buy Rating for Boston Scientific (BSX)J P Morgan Chase & Co Reiterates Buy Rating for Boston Scientific (BSX)
www.americanbankingnews.com - November 29 at 1:50 PM
Oppenheimer Reaffirms "Hold" Rating for Boston Scientific (BSX)Oppenheimer Reaffirms "Hold" Rating for Boston Scientific (BSX)
www.americanbankingnews.com - November 29 at 10:48 AM
Boston Scientific Delays Commercialization Of LOTUS Edge Aortic Valve SystemBoston Scientific Delays Commercialization Of LOTUS Edge Aortic Valve System
www.finanznachrichten.de - November 29 at 9:56 AM
Boston Scientific Corp. (BSX) Dropped To A 3-Month LowBoston Scientific Corp. (BSX) Dropped To A 3-Month Low
www.rttnews.com - November 29 at 9:56 AM
Boston Scientific Announces Update on LOTUS Edge™ Aortic Valve SystemBoston Scientific Announces Update on LOTUS Edge™ Aortic Valve System
finance.yahoo.com - November 29 at 9:56 AM
Boston Scientific loses $3B in value prior to announcing product delayBoston Scientific loses $3B in value prior to announcing product delay
finance.yahoo.com - November 29 at 9:56 AM
Boston Scientific (BSX) PT Lowered to $35.00 at Canaccord GenuityBoston Scientific (BSX) PT Lowered to $35.00 at Canaccord Genuity
www.americanbankingnews.com - November 29 at 9:35 AM
Boston Scientific Corporation (BSX) Short Interest Up 33.3% in NovemberBoston Scientific Corporation (BSX) Short Interest Up 33.3% in November
www.americanbankingnews.com - November 29 at 2:38 AM
Boston Scientific Corp. (BSX) Is Sinking In Early TradeBoston Scientific Corp. (BSX) Is Sinking In Early Trade
www.nasdaq.com - November 28 at 4:59 PM
The Biggest Loser: Boston Scientific Drops 7.4%The Biggest Loser: Boston Scientific Drops 7.4%
finance.yahoo.com - November 28 at 4:59 PM
Boston Scientific To Participate In Citi 2017 Global Healthcare ConferenceBoston Scientific To Participate In Citi 2017 Global Healthcare Conference
finance.yahoo.com - November 27 at 6:27 PM
ETFs with exposure to Boston Scientific Corp. : November 27, 2017ETFs with exposure to Boston Scientific Corp. : November 27, 2017
finance.yahoo.com - November 27 at 6:27 PM
Biogen taps former Boston Scientific exec as next CFO - Boston Business JournalBiogen taps former Boston Scientific exec as next CFO - Boston Business Journal
www.bizjournals.com - November 22 at 10:30 PM
Quant Score Keep Boston Scientific (BSX) a BuyQuant Score Keep Boston Scientific (BSX) a Buy
investorplace.com - November 21 at 11:27 AM

SEC Filings

Boston Scientific (NYSE:BSX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Boston Scientific (NYSE:BSX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Boston Scientific (NYSE BSX) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.